Investigation the effect of ginger powder on NF-KB, Ox-LDL, lipid profile and clinical symptoms in Rheumatoid arthritis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016083129508N2

Enrollment

Registered

2016-10-08

Start date

2015-02-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis. Rheumatoid arthritis with splenoadenomegaly and leukopenia

Interventions

Intervention 1: intervention group: receiving ginger tablet 1.5 gr/day for 8 weeks. Intervention 2: placebo group: placebo tablet 1.5 gr/day) for 8 weeks.

intervention group: receiving ginger tablet 1.5 gr/day for 8 weeks

placebo group: placebo tablet 1.5 gr/day) for 8 weeks

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: rheumatoid arthritis patients; age group 25-75 years. Exclusion Criteria including: pregnancy and breastfeeding; mellitus diabetes; thyroid and kidney disorders; smoking; infectors myocardial; hyperthyroidism; NF-KB, Ox-LDL, Lipid profile and clinical symptoms before and after intervention were compared between two groups.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Number of swollen joint. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: The clinical diagnosis.;NF-KB. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: Ng/ml.;OxLDL. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: Ng/L.;HDL-C. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;LDL-C. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;TC. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;TG. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;ESR. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: Ml/hr.;RF. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: -/+.	—

Measure

Time frame

Number of swollen joint. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: The clinical diagnosis.;NF-KB. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: Ng/ml.;OxLDL. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: Ng/L.;HDL-C. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;LDL-C. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;TC. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;TG. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: mg/dl.;ESR. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: Ml/hr.;RF. Timepoint: before intervention, 8 weeks after intervention. Method of measurement: -/+.

—

Secondary

Measure	Time frame
Pain. Timepoint: before intervention, 3 months after intervention. Method of measurement: according visual analog scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Rasoul Zarrin

Urmia University of Medical Sciences

wwzarrin@yahoo.com; rasoul.zarrin@uqconnect.edu.au+98 44 3346 9935

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026